Valneva's 15min chart shows KDJ Death Cross, Bearish Marubozu formation.
ByAinvest
Thursday, Oct 9, 2025 1:06 pm ET1min read
VALN--
The delay in the Phase 3 data release, which was initially expected in late 2025, has been pushed back to the first half of 2026. Additionally, Valneva has revised its financial guidance for 2025, lowering its revenue projections from €180-190 million to €165-180 million and reducing its R&D investments from €90-100 million to €80-90 million [1][2].
The company cited "ongoing uncertainty" due to the FDA's suspension of the IXCHIQ vaccine license, which has further dampened investor confidence. Despite the challenges, Valneva has secured a debt facility for up to $500 million with Pharmakon Advisors, LP, extending its debt repayment timeline from Q1 2026 to Q4 2030. The new financing also includes more favorable terms, such as a lower interest rate and improved structure with a bullet maturity after five years [2].
Technical analysis of Valneva's 15-minute chart indicates a bearish trend, with a KDJ Death Cross and Bearish Marubozu pattern observed on October 9th, 2022 at 13:00. This suggests that the momentum of the stock price is shifting towards a downward trend, with potential for further decline. Sellers currently dominate the market, and this bearish momentum is likely to persist .
Based on the technical analysis of Valneva's 15-minute chart, a KDJ Death Cross and Bearish Marubozu pattern was observed on October 9th, 2022 at 13:00. This suggests that the momentum of the stock price is shifting towards a downward trend, with potential for further decline. Sellers currently dominate the market, and this bearish momentum is likely to persist.
Valneva SE (NASDAQ: VALN) has seen a significant decline in its stock price following the delay in the release of Phase 3 data for its Lyme disease vaccine and the suspension of its IXCHIQ vaccine by the FDA. The company's shares fell by 7% on the day of the announcement, with analysts attributing the drop to the uncertainty surrounding the vaccine's future [1].The delay in the Phase 3 data release, which was initially expected in late 2025, has been pushed back to the first half of 2026. Additionally, Valneva has revised its financial guidance for 2025, lowering its revenue projections from €180-190 million to €165-180 million and reducing its R&D investments from €90-100 million to €80-90 million [1][2].
The company cited "ongoing uncertainty" due to the FDA's suspension of the IXCHIQ vaccine license, which has further dampened investor confidence. Despite the challenges, Valneva has secured a debt facility for up to $500 million with Pharmakon Advisors, LP, extending its debt repayment timeline from Q1 2026 to Q4 2030. The new financing also includes more favorable terms, such as a lower interest rate and improved structure with a bullet maturity after five years [2].
Technical analysis of Valneva's 15-minute chart indicates a bearish trend, with a KDJ Death Cross and Bearish Marubozu pattern observed on October 9th, 2022 at 13:00. This suggests that the momentum of the stock price is shifting towards a downward trend, with potential for further decline. Sellers currently dominate the market, and this bearish momentum is likely to persist .
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet